Pazopanib in Sarcoma: Clinically Significant Benefit? - Medscape News

May 16, 2012 — The clinical trial showing benefit from pazopanib (Votrient) in soft tissue sarcoma, which was the basis for the drug's recent approval for this indication, was published online today in the Lancet. The trial, known as PALLETE (Pazopanib ...

GlaxoSmithKline: CHMP Recommends Authorization For Pazopanib - 4-traders (press release)

GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the pharmaceutical company, said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Votrient ...

Pazopanib Works as Sarcoma Salvage Tx - MedPage Today

Nurse Planner Patients with metastatic soft tissue sarcoma who failed standard chemotherapy had improved progression-free survival when they were treated with pazopanib (Votrient), researchers said. Median progression-free survival among ...

GlaxoSmithKline's 4.8% Yield Makes It Attractive With Or Without Human Genome Takeover - Seekingalpha.com

Patients with advanced soft tissue sarcoma who have received chemotherapy in the past can now use a drug called Votrient. Votrient was not approved for use in patients with adipocytic STS or gastrointestinal stromal tumors, but Votrient should still be an ...

Brain mets found - what do I do now? - American Cancer Society

However, they then found two more areas of her spine, which they decided to wait on treating to see if the Votrient would help - she started this drug 3 weeks ago. She was given calcium treatments to bring down her calcium levels (as that we the reasoning ...

Can't believe how you have to double check everything - American Cancer Society

Then the oncologist that she decided to go with met with her in the hospital and said his office would get things rolling so she could start Votrient. I called there 2 days after she was released and they hadn't done a thing about it even though it was ...

Research Identifies Important Proteins that Play Role in Sarcoma Cancer Growth - eMaxHealth.com

Votrient (pazopanib) belongs to a class of medications called tyrosine kinase inhibitors which works by slowing or stopping the spread of cancer cells. These tyrosine kinases are the focus of new research for potential new treatments of sarcoma by ...

Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality Reduction - msnbc.com

Oxaliplatin (Eloxatin), Pazopanib (Votrient), Pemetrexed (Alimta), Pertuzumab (Omnitarg), Pixantrone, Pralatrexate (Folotyn), Raloxifene (Evista), Ramucirumab, Ridaforolimus (MK-8669), Sorafenib (Nexavar), Trastuzumab (Herceptin), Trastuzumab ...

Research and Markets: Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - Yahoo Finance

All of the novel targeted therapies (Votrient (pazopanib) in 2014, TH-302 in 2015, Yondelis (trabectedin) and Halaven (eribulin mesylate) in 2016) are also expected to be launched in the forecast period. These will replace the existing off-label ...

Targeted Therapies Drive the Global Renal Cell Carcinoma (RCC) Drugs Market, According to New Report by Global Industry Analysts, Inc. - San Francisco Gate

However, going forwards, it is estimated that GlaxoSmithKline's Votrient could threaten the dominance of Pfizer's Sutent, the long-established leader in the global RCC drugs market. Also, despite the fact that Multikinase Inhibitors dominate the ...